InvestorsHub Logo

modrica

09/09/16 1:18 PM

#3132 RE: modrica #3131

Analysts see Delcath getting FDA approval in 2017

http://www.bizjournals.com/albany/blog/2013/05/analysts-see-delcath-getting-fda.html

older article but interesting

imo

gl

mod

ash111

09/09/16 2:31 PM

#3134 RE: modrica #3131

agree and based on last 10Q only,cash burn rate was about 5m(for six month).i would say 40m(cash+resticted) should be sufficient for 3 yrs.imo

closed $35m Funding Round in June.

ash111

09/16/16 11:58 AM

#3140 RE: modrica #3131

I found it very interesting due to Delcath receives new FDA approval back in 2015 for "a type of liver cancer that affects bile ducts". it seems they did some major steps forward since then( beside closed $35 Million Funding Round back in June 2016,"One of the targets is in the Phase 2 and Phase 3 study of its Melphalan/HDS").

http://poststar.com/business/local/delcath-receives-new-fda-approval/article_0d206ce0-cfe0-5fa2-97cc-d7c911d1848d.html

DCTH ($6m cap Company, 1.5m O/S) mentioned, just recently, as a major key player for Bile Duct Cancer,among big name companies : http://finance.yahoo.com/news/world-bile-duct-cancer-cholangiocarcinoma-150500717.html

based on last 10Q only,cash burn rate was about 5m(for six month).i would say 40m(cash+restricted) should be sufficient for 3 yrs.imo

Many events (Sept/Oct/Nov) makes it more interesting: http://delcath.com/reuters-events-roll/